Results 31 to 40 of about 14,173 (271)

Consenso mexicano de cáncer mamario. Manejo del cáncer de mama temprano

open access: yesGaceta Mexicana de Oncolog�a
El cáncer mamario en estadios tempranos tiene un manejo local (quirúrgico y radioterapia) y sistémico específico. Este tipo de cáncer incluye el carcinoma ductal in situ y los cánceres de mama en estadios I, IIA, IIB y IIIA. Esta décima actualización del Consenso Mexicano de Cáncer Mamario abordó el manejo de los estadios tempranos. La difusión de este
Juan E. Bargalló-Rocha   +28 more
openaire   +2 more sources

Câncer de Mama

open access: yesRevista Brasileira de Cancerologia, 2001
Conduta diagnóstico-terapêutica do INCA para Câncer de Mama.
Instituto Nacional de Câncer
doaj   +1 more source

Consenso mexicano de cáncer mamario. Manejo del cáncer de mama avanzado

open access: yesGaceta Mexicana de Oncolog�a
El cáncer de mama es la neoplasia más frecuente y con mayor mortalidad en mujeres en todo el mundo. La décima actualización del Consenso Mexicano Sobre Diagnóstico y Tratamiento del Cáncer Mamario (2023) es publicada por sus autores en diferentes artículos.
Guadalupe Cervantes-Sánchez   +20 more
openaire   +2 more sources

Consenso mexicano de cáncer mamario. Manejo del cáncer de mama en poblaciones especiales

open access: yesGaceta Mexicana de Oncolog�a
El cáncer mamario en poblaciones especiales (mujeres jóvenes, de edad avanzada, en embarazo o lactancia, hombres) requiere de consideraciones especiales de manejo sistémico, quirúrgico y radioterapia. La décima actualización del Consenso Mexicano Sobre Diagnóstico y Tratamiento del Cáncer Mamario (Colima, enero de 2023) es publicada por sus autores en ...
Laura Torrecillas-Torres   +16 more
openaire   +2 more sources

Cancer Health Disparities Among Patients With Early-Stage Estrogen Receptor–Positive Breast Cancer: Impact of Public Versus Private Health Care on Diagnosis-to-Treatment Interval in Brazil

open access: yesJCO Global Oncology
PURPOSEIn 2013, Brazil implemented a federal law (Law 12.732/2012) mandating cancer treatment to begin within 60 days of diagnosis. Among women with newly diagnosed estrogen receptor–positive (ER+) nonmetastatic breast cancer, we describe the diagnosis ...
Romualdo Barroso-Sousa   +20 more
doaj   +1 more source

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer

open access: yesnpj Breast Cancer
Neoadjuvant pembrolizumab plus chemotherapy (P + CT) has emerged as a standard of care for stage II-III triple-negative breast cancer (TNBC). However, the best anthracycline-cyclophosphamide (AC) schedule remains to be determined.
Renata Colombo Bonadio   +22 more
doaj   +1 more source

Self-care and breast cancer prevention: perceptions of women with motor disabilities / Autocuidado e prevenção de câncer de mama: percepções de mulheres com deficiência motora

open access: yesRevista de Pesquisa Cuidado é Fundamental Online, 2023
Objetivo: conhecer a percepção das mulheres com deficiência quanto ao autocuidado e prevenção do câncer de mama. Método: estudo transversal, descritivo e qualitativo no qual participaram 11 mulheres com deficiência.
Diego Augusto Lopes Oliveira   +5 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Câncer de mama em mulheres com idade igual ou superior a 65 anos: estudo de probabilidade de sobrevida livre de doença [PDF]

open access: yes, 2006
Dissertação (mestrado) - Universidade Federal de Santa Catarina. Centro de Ciências da Saúde. Programa de Pós-Graduação em Ciências Médicas.O câncer de mama é a principal neoplasia malígna que acomete as mulheres e cerca de 50% dos casos ocorrem a partir
Traebert, Érica Elaine
core  

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study

open access: yesBreast
Background: In pivotal CDK4/6 inhibitor (CDK4/6i) adjuvant trials, most patients received chemotherapy (CT). However, the role of CDK4/6i in patients spared CT by a genomic signature remains unclear.
Leandro Jonata de Carvalho Oliveira   +28 more
doaj   +1 more source

Home - About - Disclaimer - Privacy